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Background: The availability of anaphylaxis guidelines and of medications, supplies, and equipment for the assessment and
management of anaphylaxis by allergy-immunology specialists in health care settings worldwide is unknown.
Objective: To ascertain the global availability of these essentials.
Methods: A survey instrument was developed and sent by e-mail in 2008 to a nonrandomized convenience sample of
representative leading allergy-immunology specialists in 52 countries identified through the World Allergy Organization.
Responses were analyzed by country.
Results: Surveys were returned from 44 of 52 countries on 6 continents, for an 85% response rate. Anaphylaxis guidelines
were reported to be in use in 70% of the 44 responding countries. The diagnosis of acute anaphylaxis was reported to be based
on clinical history and physical examination alone in 63% of responding countries. Medications for anaphylaxis treatment were
reported to be available in the 44 responding countries as follows: epinephrine (adrenaline) for injection, 100%; any intravenous
glucocorticoid, 89%; any intravenous H1-antihistamine, 77%; any intravenous H2-antihistamine, 70%; glucagon, 73%; atropine,
73%; dopamine, 86%; noradrenaline, 70%; vasopressin, 64%; and a 2-agonist for nebulization, 86%. Supplies and equipment
for anaphylaxis treatment were reported to be available in responding countries as follows: for giving supplemental oxygen, 95%;
for intubation, 89%; for giving intravenous fluid resuscitation, 91%; for monitoring oxygenation using pulse oximetry, 91%; and
for continuous noninvasive blood pressure and cardiac monitoring, 81%.
Conclusions: Allergy-immunology specialists reported that except for epinephrine ampules life-saving essentials for the
assessment and management of anaphylaxis in health care settings were not universally available worldwide in 2008.
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INTRODUCTION
The worldwide burden of anaphylaxis, a severe, life-threat-
ening generalized or systemic hypersensitivity reaction,1–3 is
difficult to quantify. Although anaphylaxis is a high priority
public health issue in some countries, it is still considered to
be a rare disease in many other countries. The reported rate of
occurrence appears to vary widely from one country to an-
other. The lifetime prevalence has been estimated at 0.05% to
2% based on international studies.4
To increase awareness of anaphylaxis, to help improve
standards of care for the diagnosis and treatment of anaphy-
laxis worldwide, and to contribute to anaphylaxis education,
global anaphylaxis guidelines are being developed by the
World Allergy Organization (WAO). The WAO is an inter-
national federation of regional and national allergy and clin-
ical immunology societies dedicated to advancing excellence
in clinical care, research, education, and training in allergy
and clinical immunology.
Ascertaining how anaphylaxis is defined, diagnosed, and
treated around the globe is an important preliminary step
toward development of the WAO anaphylaxis guidelines. We
hypothesized that availability of national guidelines and of
medications, supplies, and equipment for assessment and
management of anaphylaxis in health care settings as reported
by allergy-immunology specialists might vary considerably
worldwide. We tested this hypothesis by conducting a survey
of allergy-immunology specialists in the WAO.
METHODS
A survey instrument was designed to focus on the assessment
and management of anaphylaxis by allergy-immunology spe-
cialists in health care settings (hospitals, clinics, and medical
offices) worldwide, particularly with regard to availability of
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national anaphylaxis guidelines and of essential medications,
supplies, and equipment. This survey, containing 14 multiple-
choice, multipart questions in English, was sent by e-mail in
2008 to a nonrandomized, cross-sectional, convenience sam-
ple (in epidemiologic terms) of allergy-immunology special-
ists from 52 different countries, with the aim of obtaining 1
response per country. These physicians were among the lead-
ing allergy-immunology practitioners, teachers, and research-
ers in the world, as identified through the WAO House of
Delegates, which at any given time contains a balanced
representation of allergy-immunology specialists from all
global regions and all countries where the specialty is estab-
lished or is becoming formally established.
Translation of the survey was provided if needed. If no
response to the initial e-mail survey was received, the e-mail
address was vetted and the survey was re-sent in up to 4
follow-up e-mails.
The physicians were asked to focus on the country in
which their clinical work in allergy-immunology was per-
formed and to provide information about the definition of
anaphylaxis in use and the anaphylaxis guidelines in use, if
any. They were asked how the diagnosis of an acute anaphy-
laxis episode was made and to report on the availability of
medications, supplies, and equipment for treatment of such
episodes. There were specific questions about availability of
medications such as epinephrine (adrenaline), H1-antihista-
mines, H2-antihistamines, 2-adrenergic agonists, glucocorti-
coids, glucagon, atropine, dopamine, noradrenaline, and va-
sopressin.
The physicians were also asked about availability of oxy-
gen and other supplies and equipment needed for airway
management, intravenous fluids and other supplies and
equipment for shock management, equipment for monitoring
patients, and about the body position in which patients were
placed during treatment. In addition, they were asked how
patients discharged from a health care facility were prepared
to manage anaphylaxis recurrences in the community, about
availability of tests to confirm allergen sensitization, and
about common triggers of anaphylaxis in their country.
In 4 instances in which 2 physicians responded from a
country, 1 of the 2 responses was randomly selected for
inclusion in the database. Responses were analyzed by coun-
try and expressed as percentage of countries from which a
response to each specific question was received.
RESULTS
Surveys were returned from 44 of 52 countries on 6 conti-
nents, for a response rate of 85%. The continents and coun-
tries represented were Africa and the Middle East (Egypt,
South Africa, Lebanon, Israel), Asia (Bangladesh, China,
India, Japan, South Korea, Malaysia, Singapore, Thailand,
Vietnam), Europe (Austria, Bulgaria, Czech Republic, Den-
mark, France, Germany, Greece, Hungary, Iceland, Italy,
Netherlands, Poland, Portugal, Romania, Russia, Serbia/
Montenegro, Spain, Switzerland, Turkey, Ukraine, United
Kingdom), South America (Argentina, Brazil, Chile, Uru-
guay, Venezuela), North America (Canada, Mexico, and the
United States), and Australia and New Zealand.
Most physicians responding to the survey provided com-
plete answers to each of the specific multipart questions. This
is described throughout as “responses were received from 44
of the 52 countries” or “in/of the 44 responding countries.”
For 2 of the multipart questions, complete responses were
received from only 43 of the 52 countries, and this is de-
scribed in the “Results” section and tables as “responses were
received from 43 of the 52 countries” or “in/of the 43 re-
sponding countries.”
The definitions of anaphylaxis reported to be in use in the
44 responding countries, as summarized in Table 1, were the
WAO definition (“anaphylaxis is a severe life-threatening
generalized or systemic hypersensitivity reaction”);1 the Eu-
ropean Academy of Allergology and Clinical Immunology
(EAACI) definition,2 which is identical to the WAO defini-
tion; and/or the National Institute of Allergy and Infectious
Disease/Food Allergy and Anaphylaxis Network (NIAID/
FAAN) definition (“anaphylaxis is a serious allergic reaction
that is rapid in onset and may cause death”).3
National anaphylaxis guidelines, defined as those devel-
oped within the responding physician’s own country, were
reported to be in use in 36% of the 44 responding countries
(Table 1). These guidelines were published in different lan-
guages and formats, including print medical journals, online
medical journals, booklets, bulletins, circulars, protocols,
Table 1. Availability of National Anaphylaxis Guidelines and
Definition of Anaphylaxis Used
Anaphylaxis definitions and guidelines
Responding
countries, %
(N  44)a
Definition of anaphylaxis used
World Allergy Organization definition 73
NIAID/FAAN definition 36
Other definitions (eg, EAACI definition) 7
No definition 2
Anaphylaxis guidelines useda,b
National guidelinesc 36
Other guidelinesd 34
Both national and other guidelines 7
Neither national nor other guidelines 30
Abbreviations: EAACI, European Academy of Allergology and Clinical
Immunology; FAAN, Food Allergy and Anaphylaxis Network; NIAID,
National Institute of Allergy and Infectious Diseases.
a Numbers add up to more than 100% because more than 1 definition
or guideline was used in some countries.
b Guidelines, in any language or format, as defined by the responders.
c Guidelines developed in the responder’s country.
d Guidelines developed in a country other than the responder’s, most
commonly the Anaphylaxis Practice Parameter of the American Acad-
emy of Allergy, Asthma, and Immunology and the American College of
Allergy, Asthma, and Immunology, but also the guidelines of the
Resuscitation Council (United Kingdom) or the Australasian Society of
Clinical Immunology and Allergy.5–7
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and/or Web sites.5–14 They varied in scope and comprehen-
siveness. “Other” anaphylaxis guidelines,5–7 defined as those
developed in a country different from the responding physi-
cian’s own country, were in use in 34% of the 44 responding
countries (Table 1). No anaphylaxis guidelines were report-
edly used by allergy-immunology specialists in 30% of the
responding countries.
In 63% of 43 responding countries, the diagnosis of acute
anaphylaxis was reported to be based on clinical history and
physical examination alone. Laboratory tests, such as mea-
surement of serum total tryptase levels or plasma or 24-hour
urine histamine levels, were available to confirm the clinical
diagnosis in only 37% of the responding countries.
For the management of an acute anaphylaxis episode,
epinephrine (adrenaline) in ampule formulations for injection
by any route was reported to be available in all of the 44
responding countries (Table 2). One or more intravenous
glucocorticoids and 1 or more intravenous H1-antihistamines,
as well as an inhaled 2-adrenergic agonist by nebulizer and
compressor, were available in many, but not all, countries. An
intravenous H2-antihistamine, glucagon, atropine, dopamine,
noradrenaline, and vasopressin were not universally avail-
able. All the basic medications considered to be necessary, as
defined by expert opinion5,6 (injectable epinephrine, glu-
cocorticoid, antihistamines, glucagon, atropine, and 1 vaso-
pressor in addition to epinephrine, as well as a 2-agonist for
nebulization), were available in 54% of the 44 responding
countries (Table 2).
In most of the 43 responding countries, supplemental ox-
ygen was reported to be available and was usually delivered
by facemask at a rate of 6 to 8 L/min; also, supplies and
equipment for intubation were available in 89% of these
countries (Table 3). In addition, in most of the 43 countries,
intravenous fluids were reported to be available for the man-
agement of hypotension and shock; for example, in more than
90% of these countries, rapid administration of a crystalloid,
usually isotonic saline, was possible (Table 3).
In almost all of 43 responding countries, it was reported
that monitoring of vital signs (eg, measurement of blood
pressure using a sphygmomanometer and stethoscope) could
be performed at intervals by health care professionals; how-
ever, supplies and equipment for continuous noninvasive
monitoring of blood pressure and heart rate and pulse oxime-
ters for measurement of oxygen saturation were not univer-
Table 3. Other Aspects of Acute Anaphylaxis Management
Variable
Responding
countries, %
(N  43)
Management of the airway
Supplemental oxygen available 95
Route of Delivery
Facemask 79
Oropharyngeal airway 66
Nasal prongs 58
Supplies and equipment available for
intubation
89
Cricothyroidotomy 36
Management of hypotension and shock
Intravenous fluids available 98
Type of intravenous fluid given initially (ie,
during the first 30 minutes of treatment)
Isotonic saline 91
Lactated Ringer’s solution 42
Colloid 12
Body position recommended
Back 64
Position of comfort 19
Side 14
Sitting 2
Monitoring in the health care settinga
Frequent measurement of blood pressure
and heart rate by physician or nurse
98
Pulse oximetry 91
Continuous noninvasive cardiac
monitoring
81
Urine output 74
a The location in which the patients are monitored varies depending
on the severity of the episode; however, in 48% of countries, this
reportedly occurs in an emergency department or in an emergency
department holding unit.
Table 2. Availability of Medications for Acute Anaphylaxis
Treatment
Medication
Responding
countries, %
(N  44)
Epinephrine (adrenaline) ampulesa 100
Other medications
Glucocorticoidb,c (any intravenous formulation) 89
2-adrenergic agonist (by
nebulizer/compressor)d
86
H1-antihistamine (any intravenous
formulation)b,e
77
H2-antihistamine (any intravenous
formulation)f
70
Glucagon 73
Atropine 73
Vasopressors in addition to epinephrine
Dopamine 86
Noradrenaline 70
Vasopressin 64
All of the above medications availableg 54
a For injection by any route (intramuscular [most common], subcuta-
neous, or intravenous [least common]).
b Medication, dose, and duration of treatment varied.
c Hydrocortisone or methylprednisolone.
d Albuterol (salbutamol) or levalbuterol.
e Chlorpheniramine, diphenhydramine, hydroxyzine, or promethazine.
f Cimetidine or ranitidine.
g Defined by expert opinion5,6,22–26 as epinephrine, an intravenous
glucocorticoid, H1-antihistamine, H2-antihistamine, glucagon, atro-
pine, and 1 of dopamine, noradrenaline, or vasopressin; and a 2-
adrenergic agonist for nebulization.
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sally available (Table 3). In most of the 43 countries, it was
reported that patients were placed on the back or in a position
of comfort during treatment of an acute anaphylaxis episode.
In 63% of the countries, patients were kept in a physician-
monitored health care setting for at least 4 hours after the
initial anaphylaxis symptoms resolved.
In most of the 44 responding countries, patients discharged
from a health care setting after treatment of an acute anaphy-
laxis episode were reported to be equipped with epinephrine
or a prescription for epinephrine to treat anaphylaxis recur-
rences in the community as an autoinjector, ampule with
syringe, prefilled syringe, or metered-dose inhaler (Table 4).
In half of the countries, some form of an anaphylaxis emer-
gency action plan and some form of medical identification for
patients stating their risk for anaphylaxis recurrence and their
anaphylaxis trigger(s) were recommended (Table 4).
All tests considered to be necessary for confirming allergen
sensitization and clinical risk of anaphylaxis recurrence, de-
fined as skin prick tests, intradermal tests, allergen specific
IgE measurement, and challenge or provocation tests, were
reported to be available in 60% of the 44 responding coun-
tries (Table 5). Common triggers of anaphylaxis, also sum-
marized in Table 5, were reported to include a wide variety of
foods, medications, insect stings and bites, natural rubber
latex, radiocontrast media and medical dyes, and allergen
immunotherapy. Some triggers, such as Anisakis simplex and
hydatid cyst, although uncommonly reported, were important
considerations in specific geographic areas.
DISCUSSION
The results of this unique study reflect global availability of
guidelines, medications, supplies, and equipment for the as-
Table 4. Preparing Patients for Anaphylaxis Recurrence in the
Community
Variable
Responding
countries, %
(N  44)
Medications at time of discharge from the
health care setting
Epinephrine/adrenaline (all formulations)a 91
H1-antihistamineb 86
Other aspects of discharge management
Anaphylaxis emergency action plan 53
Medical identification (eg. bracelet or card) 49
Chart sticker 51
Electronic chart flag 35
a In 9% of the countries, no epinephrine formulation was prescribed at
discharge. In an additional 19% of the countries, epinephrine was
available only in a metered-dose inhaler formulation (ie, could not be
injected).
b A total of 13 different orally administered H1-antihistamines were
recommended: 8 sedating first-generation medications (ie, chlorphe-
niramine, clemastine, dimethindene, diphenhydramine, hydroxyzine,
ketotifen, pheniramine, and promethazine) and 5 nonsedating sec-
ond-generation H1-antihistamines (ie, cetirizine, desloratadine, fexo-
fenadine, levocetirizine, and loratadine)
Table 5. Tests and Triggers for Anaphylaxis
Tests and triggers
Responding
countries, %
(N  44)
Postdischarge availability of tests to confirm
allergen sensitizationa
Skin prick tests with allergenb 91
Allergen specific IgE measurements in serum 91
Challenge or provocation testsc 77
Intradermal tests with allergen 70
All of the above tests (skin prick and
intradermal tests, specific IgE levels, and
challenge tests)
60
Triggers of anaphylaxisa
Medicationsd 100
Foods, including spices and other additivese 98
Insect stings and bitesf 93
Idiopathic (no trigger identified) 67
Radiocontrast media and medical dyes 57
Exercise, usually in association with food
ingestion
48
Natural rubber latex 40
Allergen immunotherapy 31
Allergen skin tests 10
Anisakis simplex 9
Hydatid cyst 5
Other (vaccines to prevent infectious disease,
seminal fluid, cosmetics, cold,
aeroallergens, eg, horse dander)
4
a Numbers add up to more than 100% because multiple triggers of
anaphylaxis were reported from all countries
b Skin prick tests used for foods, venoms, medications (including
local anesthetics), latex, airborne allergens, Anisakis simplex, and
radiocontrast media.
c Challenge and provocation tests used for foods, medications, local
anesthetics, Hymenoptera venoms, and exercise.
d Medication triggers included -lactam antibiotics (penicillin, ampi-
cillin, cloxacillin, ceftriaxone and other cephalosporins, and quino-
lones) and antibiotics from other classes, including sulfas and antitu-
berculosis drugs, such as streptomycin; anticancer drugs (taxanes,
platins, and monoclonal antibodies, such as cetuximab); other mono-
clonal antibodies, such as infliximab and omalizumab; central nervous
system drugs, including anticonvulsants, drugs for insomnia (seda-
tives), opioids, analgesics, and antipyretics, including nonsteroidal
anti-inflammatory drugs, such as acetylsalicylic acid, paracetamol
(acetaminophen), and dipyrone; neuromuscular blockers, general an-
esthetics; local anesthetics; proton pump inhibitors; and vitamins.
e Food triggers included peanut and other legumes, including chickpea
(Bengal gram) and lentils (eg, urad dhal); all tree nuts, including hazelnut,
cashew, and walnut; shellfish, including shrimp, crab, and mollusks;
finned fish, including sheatfish and hilsha fish; cow’s milk; goat’s milk;
egg; seeds, including sesame and sunflower; fresh fruits, including
peach, kiwi, apple, pineapple, pomegranate, citrus fruits, and exotic
fruits; vegetables, including celery and eggplant; cereals and grains,
including wheat and buckwheat; meat, including chicken and beef; and
other, including soy, spices, mugwort, bird’s nest soup, and honey.
f Insect sting or bite triggers included Hymenoptera species (eg,
honeybees, bumblebees, wasps, yellow jackets, hornets, ants [fire,
harvester, jumper, red]) and Diptera species (eg, mosquitoes and
aphids) and the arachnids spiders and scorpions.
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sessment and management of anaphylaxis in health care
settings, as reported in 2008 by representative allergy-immu-
nology specialists from 44 countries, identified through the
WAO House of Delegates.
Anaphylaxis Definitions and Guidelines
Allergy-immunology specialists reported use of modern,
broad definitions of anaphylaxis, predominantly the WAO
definition,1 the identical EAACI definition,2 or the NIAID/
FAAN definition that is accompanied by detailed criteria for
making the clinical diagnosis of anaphylaxis.3 In these defi-
nitions, no distinction is made between anaphylaxis that oc-
curs through immunologic mechanisms (commonly through
IgE and the high-affinity Fc receptor and, rarely, through
other immunologic mechanisms) and anaphylaxis that occurs
through nonimmunologic mechanisms. Hypotension or shock
are not necessarily present. The term anaphylactoid is no
longer recommended for use.
National anaphylaxis guidelines were reported to be in
used in 36% of responding countries.5–14 Guidelines devel-
oped by medical professional societies in countries other than
the responder’s own country, most commonly the American
Academy of Allergy Asthma and Immunology/American
College of Allergy, Asthma and Immunology guidelines,5
Resuscitation Council UK guidelines,6 or the Australasian
Society of Clinical Immunology and Allergy guidelines,7
were reported to be in use in 34% of countries. Of all the
guidelines reported to be in use, few were evidence based,5
and only a few were published in indexed peer-reviewed
journals5–8 and could therefore be readily identified in a
medical literature search.
In a previous systematic literature search performed by
epidemiologists, only 6 countries in the world were identified
as having national anaphylaxis guidelines.15 Some of these
guidelines were descriptive reviews that did not have the
endorsement of a national allergy society, most did not make
clear the strength of the evidence behind the recommenda-
tions made, and there were important differences in many of
the recommendations.15 The development of anaphylaxis
guidelines is, however, a dynamic, ongoing process. Since
completion of the 2008 WAO survey of essentials for the
assessment and management of anaphylaxis that is reported
here, additional national guidelines have been developed, and
additional regional guidelines have been published in indexed
peer-reviewed journals.16
Diagnosis of an Acute Anaphylaxis Episode
The diagnosis of an acute anaphylaxis episode was reported
to be based on clinical history and physical findings alone in
most countries. Laboratory tests, such as measurement of
serum total tryptase levels or plasma and urine histamine
levels, to confirm the clinical diagnosis were not widely
available. This is not necessarily a major concern unless
physicians fail to diagnose anaphylaxis in the absence of a
supporting laboratory test result.
The use of elevated tryptase or histamine levels to confirm
the diagnosis of anaphylaxis is not a component of any
anaphylaxis definition1–3; in addition, elevations in tryptase or
histamine levels are not specific for anaphylaxis.17,18 The
diagnosis of anaphylaxis depends primarily on the history of
exposure to a potential triggering agent or event, the brief
time elapsed (minutes to several hours) between exposure and
symptom onset,3 the rapid evolution of symptoms and signs,
and recognition of the pattern of target organ involvement
with approximately 40 different cutaneous, respiratory, gas-
trointestinal, cardiovascular, and/or central nervous system
symptoms.3,17,18
Even in countries where measurements of tryptase levels or
histamine levels are readily available in clinical laboratories,
these assays take several hours to perform, and results are
seldom, if ever, available on an emergency basis. In addition,
even when tryptase or histamine levels are measured in a
timely manner under optimal conditions, the levels are not
necessarily elevated in all patients with a clinical diagnosis of
anaphylaxis; for example, tryptase levels are seldom elevated
in normotensive patients or anaphylaxis triggered by food.
Moreover, tryptase and histamine levels that are within nor-
mal limits cannot be used to refute the diagnosis of anaphy-
laxis.3,17,18
Treating and Monitoring an Acute Anaphylaxis Episode
Epinephrine (adrenaline) in ampules for injection by any
route was the only medication that was universally available
for anaphylaxis treatment. This reflects the World Health
Organization position that epinephrine is an essential medi-
cation for anaphylaxis treatment (www.who.int) and also
reflects the recommendations in anaphylaxis guidelines5–16
and previous WAO anaphylaxis publications19–21 that prompt
injection of epinephrine (adrenaline) is the initial medication
of choice in anaphylaxis.
Intravenous formulations of 1 or more glucocorticoids,
H1-antihistamines, H2-antihistamines, and 2-adrenergic ago-
nists for administration by nebulizer were not universally
available worldwide. Anaphylaxis guidelines vary in their
recommendations for use of these ancillary medications.5–15
Several different H1-antihistamines for intravenous adminis-
tration are recommended in varying doses for various lengths
of time. Several different glucocorticoids for intravenous
administration are recommended in varying doses for various
lengths of time. H2-antihistamines and vasopressors in addi-
tion to epinephrine (adrenaline), such as dopamine, noradren-
aline, or vasopressin, are not listed in some guidelines.15
Nevertheless, based on decades of clinical use, consensus
opinion, and systematic reviews of the literature to date, all of
these medication classes are currently considered to play a
role in the treatment of anaphylaxis.5–17,22–25 Many of the
medications in these classes were, like epinephrine, intro-
duced for the treatment of anaphylaxis before the era of
randomized controlled trials and evidence-based medicine.
Whether they are truly essential will remain unknown until
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they are prospectively studied in randomized controlled trials
in anaphylaxis.26
Lack of availability of glucagon is a concern for patients
who are taking -adrenergic blockers and might not respond
to epinephrine. Lack of availability of atropine is a concern
for patients with anaphylaxis who develop bradycardia rather
than the more typical tachycardia. Inability to administer
epinephrine (adrenaline) by slow intravenous infusion or to
give intravenous dopamine, noradrenaline, or vasopressin is a
concern in patients with anaphylaxis that is refractory to
intramuscular epinephrine injections.3,5–7
The question has been raised, however, of whether intra-
venous infusion of potent vasopressors should be considered
to be within the scope of expertise of all allergy-immunology
specialists, particularly those working in community-based
clinics and medical offices. This is particularly true in set-
tings where infusion pumps are not available and where dose
titration against blood pressure, heart rate and function, and
oxygenation as determined by using continuous noninvasive
monitoring is not possible because of a lack of the requisite
supplies, equipment, and experienced health care profession-
als.6,7 Few national anaphylaxis guidelines provide recom-
mendations about monitoring patients with anaphylaxis; one
guideline suggests that, at a minimum, noninvasive continu-
ous blood pressure and heart rate monitoring, ability to take
a 3-lead electrocardiogram, and pulse oximetry are neces-
sary.6
Essentials for Anaphylaxis Assessment and Management
On the basis of the survey results reported here and on
existing anaphylaxis guidelines,5–16 the essentials needed for
appropriate assessment and treatment of patients with ana-
phylaxis include having a guideline (plan) and making the
clinical diagnosis of anaphylaxis promptly on the basis of the
clinical history, symptoms, and signs. Promptly and simulta-
neously place a call for help to a resuscitation team or
emergency medical services, whichever is appropriate and
available, inject epinephrine (adrenaline) intramuscularly,
and place the patient on his/her back or in a position of
comfort with the lower extremities elevated. Then, start sup-
plemental oxygen treatment, intravenous fluids, and cardio-
pulmonary resuscitation immediately, if indicated.3,5–17
In areas where resources are limited, it is particularly
important to ensure that epinephrine (adrenaline) is injected
intramuscularly as soon as anaphylaxis is recognized because
the initial first-aid dose of 0.01 mg/kg is low compared with
the dose for cardiopulmonary resuscitation, and if injected
late in patients with cardiorespiratory failure or shock, it is
likely to be ineffective.27–32 The epinephrine dose can be
repeated several times, every 5 to 15 minutes, if needed.19
Follow-up of Patients After Treatment of an Acute
Anaphylaxis Episode
The survey findings suggest that preparing and equipping
patients at risk for recurrence of anaphylaxis in community
settings5–7,17,33 is not yet a high priority in many countries.
Although epinephrine (adrenaline) was commonly prescribed
at discharge after resolution of the acute anaphylaxis episode,
it was often recommended or supplied in suboptimal formu-
lations, such as an ampule with a syringe, a prefilled syringe,
or a metered-dose inhaler,34–36 rather than an autoinjector.
This is consistent with the findings of 2 previously published
WAO surveys and probably relates to lack of availability and
affordability of epinephrine autoinjectors.20,21
The survey findings reported in this article also indicate
that many allergy-immunology specialists do not have all the
necessary materials, supplies, and equipment available to
confirm sensitization to allergens identified in the history as
potential triggers of anaphylaxis. This follow-up is important
to provide appropriate long-term management, specifically,
to provide each patient with personalized information about
avoidance of specific allergens and, where indicated, relevant
immunomodulation to reduce the likelihood of recurrent ana-
phylaxis episodes.18,37,38
Limitations of this Survey
The new information reported in this article likely represents
a best-case scenario among and within countries because the
responses were received from representative leading allergy-
immunology physicians in WAO member countries where
this specialty is established or is becoming established. The
availability of essentials for the assessment and management
of anaphylaxis is unknown in the nonresponding WAO mem-
ber countries, most of which are designated as low-resource
countries by the World Bank (www.worldbank.org) and in
the many countries that are not yet represented in the WAO
because they have few or no allergy-immunology specialists.
Also, in the responses to this survey, there were unsolicited
comments about inconsistent availability of medications in a
country, medications being available but not necessarily
within the expiry dates, and the necessity to clean and reuse
supplies intended for disposal after a single use.
An important question that needs to be addressed is
whether more information, or more reliable information,
about essentials in anaphylaxis might have been obtained
using different approaches from the one reported here. Two
alternative possibilities were considered. An independent at-
tempt could have been made to contact each of the allergy-
immunology organizations worldwide; however, this might
have resulted in overrepresentation of countries where the
specialty is well established and underrepresentation of coun-
tries where it is becoming established because of potential
difficulties in identifying and contacting colleagues in the
latter countries. A systematic literature search for anaphylaxis
guidelines could have been performed; however, as noted
previously, the results of a search published in 200715 sug-
gested that few such guidelines would be retrieved by this
method because few have been published in indexed peer-
reviewed medical journals. Indeed, this has been confirmed
by the study reported here. It is therefore likely that the
method of sampling used, specifically, obtaining information
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from allergy-immunology specialists as identified through the
WAO House of Delegates, was a reasonable one.
Implications
Lack of availability of the necessary medications, supplies,
and equipment in many countries might mean the difference
between life and death for residents and travelers who expe-
rience anaphylaxis in these countries. Improved worldwide
availability of life-saving essentials for assessment and man-
agement of anaphylaxis is needed. The global anaphylaxis
guidelines being developed by the WAO will provide infor-
mation about the basic medications, supplies, and equipment
that are absolutely necessary for assessment and manage-
ment, as well as those that are optimal.
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